The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 53, Issue 5, 2014, Pages 900-903

  Kume, Kensuke ^a   Amano, Kanzo ^a   Yamada, Susumu ^a   Kanazawa, Toshikatsu ^a   Ohta, Hiroyuki ^b   Hatta, Kazuhiko ^c   Amano, Kuniki ^d   Kuwaba, Noriko ^b  

^a Hiroshima Clinic   (Japan)

^b Department of Medical Research Hiroshima Clinic ^*  (Japan)

^c Department of Rheumatology Hatta Clinic   (Japan)

^d Sky Clinic   (Japan)

Author keywords

Anti interleukin 6 receptor antibody; Bone mineral density; Osteopenia; Rheumatoid arthritis; Tocilizumab

Indexed keywords

METHOTREXATE; TOCILIZUMAB;

ADULT; ARTICLE; BONE DENSITY; DAS28; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OSTEOPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY; BONE MINERAL DENSITY; OSTEOPENIA; RHEUMATOID ARTHRITIS; TOCILIZUMAB;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE DISEASES, METABOLIC; DRUG RESISTANCE; FEMALE; FEMUR NECK; HUMANS; INTERLEUKIN-6; LUMBAR VERTEBRAE; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84898827114     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket468     Document Type: Article

References (12)

1. Haugeberg G, Ørstavik RE, Uhlig T et al. Bone loss in patients with rheumatoid arthritis: results from a population- based cohort of 366 patients followed up for two years. Arthritis Rheum 2002;46:1720-8.
2. Haugeberg G, Uhlig T, Falch JA et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County rheumatoid arthritis register. Arthritis Rheum 2000; 43:522-30.
3. Lane NE, Pressman AR, Star VL et al. Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1995;10:257-63.
4. Lems WF, Dijkmans BA. Should we look for osteoporosis in patients with rheumatoid arthritis? Ann Rheum Dis 1998; 57:325-7.
5. Ni Y, Li H, Zhang Y et al. Association of IL-6 G-174C polymorphism with bone mineral density. J Bone Miner Metab 2013, Jun 13 [Epub ahead of print].
6. Edwards CJ, Williams E. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int 2010;21:1287-93.
7. De Vita S. Tocilizumab versus adalimumab for rheumatoid arthritis. Lancet 2013;381:1515-7.
8. Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy and adalimumab for treatment of rheumatoid arthritis (ADACTA): a randomised, doubleblind, controlled phase 4 trial. Lancet 2013;381:1541-50.
9. Dischereit G, Tarner IH, Muller-Ladner U et al. Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study. Clin Rheumatol 2013;32: 377-81.
10. Krieckaert LM, Nurmohamed MT, Wolbink G et al. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology 2013;52:547-53.
11. Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
12. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 2009; 35:745-57, vii-viii